| Revenue growth | 20.43% YoY for FY26. |
|---|---|
| Margins | FY26 EBITDA margin improved to 20.25% from 18.62%. |
| Order book | Estimated Punjab PPP project value of ₹25–26 Cr. |
| Demand visibility | Strong visibility via 10-year government PPP contracts. |
| Management confidence | High, citing strong network growth and strategic partnerships. |
Growth
FY26 revenue grew 20.43% YoY to ₹280.67 Cr; EBITDA rose 31.02% to ₹56.84 Cr with margins expanding to 20.25%.
Outlook
Targeting 100 labs across 17 states in 3 years; planning 20+ new medical centres annually.
Risks
Subject to Indian economic performance, competition in diagnostics, and technological changes.
Earnings Call filed with NSE, NSE: CHANDAN. Summary written with AI assistance from the document.
Chandan Healthcare Ltd: key numbers
- Share price
- ₹241.20
- Market cap
- ₹604.3 Cr
- Revenue (annual)
- ₹276.4 Cr
- Net profit (annual)
- ₹28.55 Cr
- P/E (TTM)
- 21.2×Sector 57.8×
- Promoter holding
- 49.61%+0.06% QoQ
- FII holding
- 0.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Chandan Healthcare Ltd
All →Chandan Healthcare Capacity Expansion
Chandan Healthcare scaled its diagnostic franchise network to 500+ centres, reaching a total of 568+ centres. It targets 1,000 centres by FY27-end and 3,000 in two years.
- diagnostic franchise collection centres
- 500 franchise centres
Chandan Healthcare Results Correction
Chandan Healthcare clarified to NSE it has one reportable segment, explaining the omission of segment-wise details in its Q4 FY27 financial results.
Chandan Healthcare Capital Structure Change
Chandan Healthcare Limited has allotted 5,99,998 equity shares upon conversion of fully convertible warrants, aggregating to ₹14.04 Crore.
- Value
- ₹14.04 Cr
Chandan Healthcare Board Meeting Outcome
Chandan Healthcare Ltd's board approved the appointment of an Independent Director, ratified cost auditor remuneration, and recommended varying the objects for utilising unutilised warrant proceeds.
Chandan Healthcare Earnings Call Transcript: Key Takeaways
Chandan Healthcare is pivoting from pharmacy trading to a high-margin diagnostic-led strategy. The company reported healthy revenue growth but is over-relying on capital-light franchise scaling to drive future profitability.
- Call
- Guides 50% growth
Chandan Healthcare Investor Presentation: Key Takeaways
Chandan Healthcare reported strong Q1 FY27 results with 19.62% YoY revenue growth and 42.27% EBITDA growth, driven by expansion into 15 states and diversified B2C, B2B, and B2G segments.